All articles by Kavya Chivukula

1. FDA approves self-administration of AstraZeneca’s asthma drug

   The US Food and Drug Administration (FDA) has approved self-administration AstraZeneca’s asthma drug Fasenra, a pre-filled, single-use auto-injector. The FDA…
   Read More…

   7 Oct
2. September’s top news stories

   Gavi Vaccine Alliance seeks $7. 4bn to immunise 300 million people Gavi, the Vaccine Alliance initiated a $7.4bn fundraising drive…
   Read More…

   5 Oct
3. FDA to review ranitidine after detecting cancer-causing contamination

   The US Food and Drug Administration (FDA) has issued a statement regarding the safety of the drug ranitidine after the…
   Read More…

   16 Sep
4. AstraZeneca receives approval to market cancer drug Tagrisso in China

   British pharmaceutical firm AstraZeneca has received regulatory approval in China to market Tagrisso as a first-line treatment for EGFR-mutated non-small…
   Read More…

   5 Sep
5. ADCendo secures loan to advance ADCs for cancer treatment

   ADCendo has secured a loan amount to advance its novel antibody-drug conjugates (ADCs) that are being developed to treat cancers….
   Read More…

   30 Aug
6. FDA approves Kyowa Kirin’s Nourianz drug for Parkinson’s disease

   The US Food and Drug Administration (FDA) has approved Japanese company Kyowa Kirin’s drug Nourianz (istradefylline) as an add-on to…
   Read More…

   29 Aug
7. Lannett agrees to distribute Posaconazole tablets in US

   Lannett Company has signed an agreement with Chinese pharmaceutical company Sinotherapeutics to distribute Posaconazole delayed-release tablets 100mg in the US….
   Read More…

   29 Aug
8. EC approves Roche’s Tecentriq combination to treat breast cancer

   Roche has gained approval from the European Commission (EC) for Tecentriq (atezolizumab) with chemotherapy (Abraxane) to treat patients with unresectable…
   Read More…

   29 Aug
9. AstraZeneca CKD drug Farxiga receives fast track designation from FDA

   AstraZeneca has received fast track designation from the US Food and Drug Administration (FDA) for Farxiga (dapagliflozin) to treat chronic…
   Read More…

   28 Aug
10. EC approves Bristol-Myers Squibb’s Empliciti to treat multiple myeloma

    The European Commission has approved Bristol-Myers Squibb’s Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone (EPd) to treat patients with refractory…
    Read More…

    28 Aug